Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Survival statistics are a way for doctors and patients to get a general idea of the outlook (prognosis) for people with a certain type of cancer. They can’t tell you how long you will live, but they might help give you a better understanding about how likely it is that your treatment will be successful.
Median survival is one way to look at outcomes. It is how long after diagnosis half the patients in a certain group are still alive. This is a middle value – half the patients live longer than this, and half do not live this long.
Survival stats are often based on previous outcomes of large numbers of people who had the disease, but they can’t predict what will happen in any particular person’s case. There are some limits to these numbers to keep in mind:
The numbers are based on people diagnosed with a myelodysplastic syndrome (MDS) some time ago. Improvements in treatment since these numbers were gathered may result in a better outlook for people now being diagnosed with MDS.
Your doctor can tell you how the numbers below apply to you.
The following survival statistics for myelodysplastic syndromes are divided by the Molecular International Prognostic Scoring System (IPSS-M) risk groups. Again, it’s important to note that this system is based largely on people who were diagnosed with MDS and treated many years ago.
IPSS-M risk group |
Median survival (years) |
Very low |
10.6 |
Low |
6 |
Moderate low |
4.6 |
Moderate high |
2.8 |
High |
1.7 |
Very high |
1 |
Remember, these survival statistics are only estimates – they can’t predict what will happen to any individual person. Many other factors can also affect a person’s outlook. We understand that these statistics can be confusing and may lead you to have more questions. Talk to your doctor to better understand your specific situation.
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
Sekeres MA, Platzbecker U. Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/prognosis-of-myelodysplastic-neoplasms-syndromes-mds-in-adults on July 3, 2024.
Last Revised: November 21, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.